


What is claimed is:

1. A compound having the formula



wherein

n is an integer from 0 to 4;

R<sub>1</sub> is halogen, trifluoromethyl, or alkyl of 1 to 6 carbons or cycloalkyl of 3 to 7 carbons;


R<sub>2</sub> and R<sub>3</sub> are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons, at least one of R<sub>2</sub> and R<sub>3</sub> being other than hydrogen;

R<sub>4</sub> is a heteroaromatic moiety which may be substituted or unsubstituted and is linked to (CH<sub>2</sub>)<sub>n</sub> via a nitrogen atom or a carbon atom; an amine (NR'R''), including those in which the amine is derived from an alpha amino acid of either natural (L) or unnatural (D) stereochemistry; an acylsulphonamide (CONHSO<sub>2</sub>R'); or a carboxylic acid amide (CONR'R'') with the proviso that when n equals zero (n = 0), then R<sub>4</sub> can only be a carboxylic acid amide or an acylsulphonamide;

R<sub>5</sub> is hydrogen or an acyl (such as acetyl or benzoyl) or other group capable of bioconversion to generate the free phenol structure (wherein R<sub>5</sub> = H);

including all stereoisomers thereof, prodrug esters thereof, and pharmaceutically acceptable salts thereof.

2. A compound as defined in Claim 1 where R<sub>4</sub> is a carboxylic acid amide (CONR'R'') in which the amine portion of the carboxylic amide can be derived from an achiral or a L or D alpha amino acid such as when the general structure -CONR'R'' can be represented by



and R', R'', R''' and R'''' are the same or different and are independently selected from hydrogen, alkyl, aryl and heteroaryl, substituted or unsubstituted, and R\* may be hydrogen, alkyl, aryl and heteroaryl, substituted or unsubstituted, and may also be any of the side chains found in the naturally occurring alpha-amino acids

3. The compound as defined in Claim 2 where R' and R\* are connected to form a 4 to 8-membered ring.
4. The compound as defined in Claim 2 where R' and R\* comprise consecutive  $-(CH_2)-$  groups to form proline or homoproline.
- 5 5. The compound as defined in Claim 1 where n is 0 or 1 or 2.
6. The compound as defined in Claim 1 wherein R<sub>2</sub> and R<sub>3</sub> are each independently halogen.
7. The compound as defined in Claim 1 wherein R<sub>2</sub> and R<sub>3</sub> are each independently an alkyl group.
- 10 8. The compound as defined in Claim 1 wherein one of R<sub>2</sub> and R<sub>3</sub> is halogen and the other is an alkyl group.
9. The compound as defined in Claim 1 wherein one of R<sub>2</sub> and R<sub>3</sub> is halogen and the other is hydrogen.
- 15 10. The compound as defined in Claim 1 wherein one of R<sub>2</sub> and R<sub>3</sub> is alkyl and the other is hydrogen.
11. The compound as defined in Claim 1 wherein R<sub>2</sub> and R<sub>3</sub> are independently Cl, Br, methyl or ethyl.
12. The compound as defined in Claim 1 wherein R<sub>1</sub> is isopropyl.
13. The compound as defined in Claim 1 wherein R<sub>4</sub> is heteroaromatic
- 20 hydrocarbon, carboxylic acid amide, or an acylsulphonamide.
14. The compound as defined in Claim 1 wherein R<sub>5</sub> is hydrogen.
15. The compound as defined in Claim 1 which is  
3,5-Dimethyl-4-(4-hydroxy-3-isopropylphenoxy)benzyltetrazole,  
3,5-Dichloro-4-(4-hydroxy-3-isopropylphenoxy)benzyltetrazole,  
25 2-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzyl]-4-thiazole acetic acid,

2-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzyl]-4-methylthiazole,

16. The compound as defined in Claim 1 which is

3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl-5-hydroxy-1-naphthalenesulphonamide,

5 3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl-4-toluenesulphonamide,

3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl-4-nitrobenzenesulphonamide,

3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl sulfamide,

3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl-5-dimethylamino-1-naphthalenesulphonamide,

10 3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl-4-aminobenzenesulphonamide,

Methyl-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl-2-sulphonamide] benzoate,

3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl-2-aminobenzenesulphonamide,

3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl-2-toluenesulphonamide,


15 3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl-4-(2-aminoethyl)benzenesulphonamide,

3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl-4-(2-aminomethyl)benzenesulphonamide,


3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl-3-nitrobenzenesulphonamide,

3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl-4-chlorobenzenesulphonamide,












20 and the compounds shown below,




17. The compound as defined in Claim 1 which is in the table below,



R=



and the compounds indicated in the table below,



-NR'R''	Formula
3-(AMINOMETHYL)PYRIDINE	C <sub>23</sub> H <sub>22</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>3</sub>
2-(2-AMINOETHYL)PYRIDINE	C <sub>24</sub> H <sub>24</sub> Br <sub>2</sub> N <sub>2</sub> O <sub>3</sub>

-NR'R''	Formula
3-(2-AMINOETHYL)PYRIDINE	C24H24Br2N2O3
2-(AMINOMETHYL)PYRIDINE	C24H30Br2N2O3
4-(AMINOMETHYL)PYRIDINE	C24H30Br2N2O3
1-(4-METHOXYPHENYL)PIPERAZINE DIHYDROCHLORIDE	C29H32Br2N2O3
1-(2-FLUOROPHENYL)PIPERAZINE	C34H32Br2N2O3
2-(2-(AMINOMETHYL)PHENYLTHIO)BENZYL ALCOHOL	C31H29Br2NO4S
2-(1-CYCLOHEXENYL)ETHYLAMINE	C25H29Br2NO3
2-AMINOINDAN	C26H25Br2NO3
2-AMINOMETHYLBENZODIOXAN	C26H25Br2NO5
3-PHENYL-1-PROPYLAMINE	C26H27Br2NO3
2-(P-TOLYL)ETHYLAMINE	C26H27Br2NO3
1-(3-AMINOPROPYL)-2-PYRROLIDINONE	C24H28Br2N2O4
BETA-ALANINE 4-METHOXY-BETA-NAPHTHYLAMIDE	C31H30Br2N2O5
2-CHLOROBENZYLAMINE	C24H22Br2ClNO3
2-AMINOMETHYL-3-CHLORODIPHENYLETHER	C30H26Br2ClNO4
DL-ALPHA-AMINO-EPSILON-CAPROLACTAM	C23H26Br2N2O4
L-PHENYLALANINOL	C26H27Br2NO4
4-(1,2,3-THIADIAZOL-4-YL)BENZYLAMINE	C26H23Br2N3O3S
2-AMINOMETHYLTHIOPHENE	C22H21Br2NO3S
1-(1-NAPHTHYL)ETHYLAMINE	C29H27Br2NO3
3-CHLORO-4-METHYL BENZYLAMINE	C25H24Br2ClNO3
TETRAHYDROFURFURYLAMINE	C22H25Br2NO4
2,4-DICHLOROPHENETHYLAMINE	C25H23Br2Cl2NO3
ETHYL 4-AMINO-1-PIPERIDINECARBOXYLATE	C25H30Br2N2O5
2,6-DIFLUOROBENZYLAMINE	C24H21Br2F2NO3
2-IODOBENZYLAMINE	C24H22Br2INO3
2-METHYLBENZYLAMINE	C25H25Br2NO3
BENZYLAMINE	C24H23Br2NO3
3-METHYLBENZYLAMINE	C25H25Br2NO3
2-METHOXYPHENETHYLAMINE	C26H27Br2NO4
3-METHOXYPHENETHYLAMINE	C26H27Br2NO4
2-ETHOXYBENZYLAMINE	C26H27Br2NO4
(R)-(-)-1-CYCLO-HEXYLETHYLAMINE	C25H31Br2NO3
4-METHOXYPHENETHYLAMINE	C26H27Br2NO4
2-FLUOROBENZYLAMINE	C24H22Br2FNO3
2-CHLORO-6-METHYLBENZYLAMINE	C25H24Br2ClNO3
4-CHLOROBENZYLAMINE	C24H22Br2ClNO3
BETA-METHYLPHENETHYLAMINE	C26H27Br2NO3
1,1-DI(P-ANISYL)METHYLAMINE	C32H31Br2NO5
MAYBRIDGE BTB 12133	C27H29Br2NO6
DL-2-AMINO-1-PENTANOL	C22H27Br2NO4
L-PHENYLALANINE P-NITROANILIDE	C32H29Br2N3O6
ETHYL 3-AMINO BUTYRATE	C23H27Br2NO5
(1S,2R)-(+)-2-AMINO-1,2-DIPHENYLETHANOL	C31H29Br2NO4
2-FLUOROPHENETHYLAMINE	C25H24Br2FNO3
2-ETHYLHEXYLAMINE	C25H33Br2NO3
3-FLUOROPHENETHYLAMINE	C25H24Br2FNO3
(1S,2S)-(+)-2-AMINO-3-METHOXY-1-PHENYL-1-PROPANOL	C27H29Br2NO5
NONYLAMINE	C26H35Br2NO3
2,5-DICHLOROBENZYLAMINE	C24H21Br2Cl2NO3
2-METHYLCYCLOHEXYLAMINE	C24H29Br2NO3
3-METHYLCYCLOHEXYLAMINE	C24H29Br2NO3
3-N-PROPOXYPROPYLAMINE	C23H29Br2NO4
2,3-DIMETHYLBENZYLAMINE	C26H27Br2NO3
3-CHLOROBENZYLAMINE	C24H22Br2ClNO3
4-TERT-BUTYLCYCLOHEXYLAMINE	C27H35Br2NO3

-NR'R''	Formula
(1S,2S)-(+)-THIOMICAMINE	C27H29Br2NO5S
2,4-DIMETHYLBENZYLAMINE	C26H27Br2NO3
2-AMINOETHYL PHENYL SULFIDE	C25H25Br2NO3S
PHENETHYLAMINE	C25H25Br2NO3
TYRAMINE	C25H25Br2NO4
L-TYROSINE METHYL ESTER	C27H27Br2NO6
BENZHYDRYLAMINE	C30H27Br2NO3
4-METHOXYBENZYLAMINE	C25H25Br2NO4
2,3-DICHLOROBENZYLAMINE	C24H21Br2Cl2NO3
GLYCINE N-BUTYL ESTER HYDROCHLORIDE	C23H27Br2NO5
D-(-)-ALPHA-PHENYLGLYCINE ETHYL ESTER HYDROCHLORIDE	C27H27Br2NO5
4-CHLORO-2-FLUOROBENZYLAMINE HYDROCHLORIDE	C24H21Br2ClFNO3
TRANS-2-PHENYLCYCLOPROPYLAMINE HYDROCHLORIDE	C26H25Br2NO3
ETHYL 4-AMINOBUTYRATE HYDROCHLORIDE	C23H27Br2NO5
DL-HOMOCYSTEINE THIOLACTONE HYDROCHLORIDE	C21H21Br2NO4S
4-NITROBENZYLAMINE HYDROCHLORIDE	C24H22Br2N2O5
NORPHENYLEPHRINE HYDROCHLORIDE	C25H25Br2NO5
GLYCINE ETHYL ESTER HYDROCHLORIDE	C21H23Br2NO5
DL-ALANINE ETHYL ESTER HYDROCHLORIDE	C22H25Br2NO5
SARCOSINE ETHYL ESTER HYDROCHLORIDE	C22H25Br2NO5
4-NITRO-N-PROPYLBENZYLAMINE HYDROCHLORIDE	C27H28Br2N2O5
PIPERIDINE	C22H25Br2NO3
3-METHYLPYPERIDINE	C23H27Br2NO3
3-(HYDROXYMETHYL)-PIPERIDINE	C23H27Br2NO4
1,2,3,4-TETRAHYDROISOQUINOLINE	C26H25Br2NO3
2-ETHYLPYPERIDINE	C24H29Br2NO3
3,4-DICHLORO-N-ETHYLBENZYLAMINE	C26H25Br2Cl2NO3
2-METHYLPYRROLIDINE	C22H25Br2NO3
N-ETHYL-N-PROPYLAMINE	C22H27Br2NO3
4-METHYLPYPERIDINE	C23H27Br2NO3
(S)-(+)-2-(METHOXYMETHYL)PYRROLIDINE	C23H27Br2NO4
N-BENZYLETHANOLAMINE	C26H27Br2NO4
DIBENZYLAMINE	C31H29Br2NO3
4-BENZYL-4-HYDROXYPIPERIDINE	C29H31Br2NO4
(R)-(-)-2-BENZYLAMINO-1-BUTANOL	C28H31Br2NO4
N-(N-ETHYLAMINOACETYL)-2,6-DIMETHYLANILINE	C29H32Br2N2O4
N-ETHYL-O-METHOXYBENZYLAMINE	C27H29Br2NO4
MAYBRIDGE NRB 01961	C30H33Br2NO5
2-((N-ETHYLAMINO)METHYL)-4-NITROPHENOL	C26H26Br2N2O6
MAYBRIDGE SEW 01484	C31H29Br2NO4S
3-AZABICYCLO-[3.2.2]NONANE	C25H29Br2NO3
N-(2-METHOXY-ETHYL)ETHYLAMINE	C22H27Br2NO4

18. The compound as defined in Claim 1 which is

*D*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]valine,

*D*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]leucine,

5 *L*-S-Benzyl, N-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]cysteine,

*D*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]tyrosine,


	1970	1971	1972	1973	1974	1975	1976	1977	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100	2101	2102	2103	2104	2105	2106	2107	2108	2109	2110	2111	2112	2113	2114	2115	2116	2117	2118	2119	2120	2121	2122	2123	2124	2125	2126	2127	2128	2129	2130	2131	2132	2133	2134	2135	2136	2137	2138	2139	2140	2141	2142	2143	2144	2145	2146	2147	2148	2149	2150	2151	2152	2153	2154	2155	2156	2157	2158	2159	2160	2161	2162	2163	2164	2165	2166	2167	2168	2169	2170	2171	2172	2173	2174	2175	2176	2177	2178	2179	2180	2181	2182	2183	2184	2185	2186	2187	2188	2189	2190	2191	2192	2193	2194	2195	2196	2197	2198	2199	2200	2201	2202	2203	2204	2205	2206	2207	2208	2209	2210	2211	2212	2213	2214	2215	2216	2217	2218	2219	2220	2221	2222	2223	2224	2225	2226	2227	2228	2229	2230	2231	2232	2233	2234	2235	2236	2237	2238	2239	2240	2241	2242	2243	2244	2245	2246	2247	2248	2249	2250	2251	2252	2253	2254	2255	2256	2257	2258	2259	2260	2261	2262	2263	2264	2265	2266	2267	2268	2269	2270	2271	2272	2273	2274	2275	2276	2277	2278	2279	2280	2281	2282	2283	2284	2285	2286	2287	2288	2289	2290	2291	2292	2293	2294	2295	2296	2297	2298	2299	2300	2301	2302	2303	2304	2305	2306	2307	2308	2309	2310	2311	2312	2313	2314	2315	2316	2317	2318	2319	2320	2321	2322	2323	2324	2325	2326	2327	2328	2329	2330	2331	2332	2333	2334	2335	2336	2337	2338	2339	2340	2341	2342	2343	2344	2345	2346	2347	2348	2349	2350	2351	2352	2353	2354	2355	2356	2357	2358	2359	2360	2361	2362	2363	2364	2365	2366	2367	2368	2369	2370	2371	2372	2373	2374	2375	2376	2377	2378	2379	2380	2381	2382	2383	2384	2385	2386	2387	2388	2389	2390	2391	2392	2393	2394	2395	2396	2397	2398	2399	2400	2401	2402	2403	2404	2405	2406	2407	2408	2409	2410	2411	2412	2413	2414	2415	2416	2417	2418	2419	2420	2421	2422	2
--	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	---

- L*-N-d-(2,2,5,7,8-Pentamethylchroman-6-sulfonyl),  
N-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]arginine,  
*L*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]aminobutyric acid,  
*L*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]valine,  
5 *L*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]leucine,  
*L*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]proline,  
*L*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]cysteine,  
N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]glycine,  
*L*-N-a-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]lysine,  
10 *D*-N-a-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]lysine,  
N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]aminoisobutyric acid,  
*L*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]phenylglycine,  
*D*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]phenylglycine,  
N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]sarcosine,  
15 *DL*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]-a-methylphenylalanine,  
*L*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]isoleucine,  
*D*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]methionine,  
*L*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]methionine,  
*L*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]phenylalanine,  
20 *D*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]phenylalanine,  
*L*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]cyclohexylalanine,  
*L*-N-e-(Benzyloxycarbonyl), N-a-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)-  
benzoyl]lysine,  
*D*-N-e-(Benzyloxycarbonyl), N-a-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)-  
25 benzoyl]lysine,  
*D*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]homoserine,  
N-[3,5-Dichloro-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]glycine,  
N-[3,5-Dichloro-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]sarcosine,  
3,5-Dichloro-4-(4-hydroxy-3-isopropylphenoxy)phenylformylimino diacetic acid,  
30 N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]-beta-alanine,  
N-[3,5-Dichloro-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]-beta-alanine,  
*D*-N-[3,5-Dichloro-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]methionine.  
*L*-N-[3,5-Dichloro-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]serine  
*D*-N-[3,5-Dichloro-4-(4-hydroxy-3-isopropylphenoxy)benzoyl]serine  
35 N-[3,5-Dichloro-4-(4-hydroxy-3-bromophenoxy)benzoyl]glycine  
N-[3,5-Dichloro-4-(4-hydroxy-3-methylphenoxy)benzoyl]glycine  
N-[3,5-Dichloro-4-(4-hydroxy-3-ethylphenoxy)benzoyl]glycine

19. The compound as defined in Claim 1 which is








*D*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]methionine,  
*L*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]methionine,  
*D*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl] α-methylalanine,  
*D*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]asparagine,  
*L*-Methyl-N-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]alanine,  
*L*-N-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]alanine,  
*L*-Dimethyl-N-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]glutamate,  
*L*-Dimethyl-N-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]glutamate,  
*L*-(*O*-*tert*-butyl)methyl-N-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]  
 glutamate,  
*L*-N-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]glutamic acid,  
*L*-N-[3,5-Dichloro-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]aspartic acid,  
*D*-di-*tert*-butyl-N-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]glutamate,  
*D*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]glutamic acid,  
*L*-*O*-*tert*-Butyl-N-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]glutamine,  
*L*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]glutamine,  
*D*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]glutamine,  
*L*-*O*-Benzyl-N-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]aspartic acid,  
*L*-*O*-*tert*-Butyl-N-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]asparagine,  
*L*-Methyl-N-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]homoserine,  
*L*-N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]homoserine,  
*D*-Methyl-N-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]homoserine,


and the compounds showed in the table below,




R	Mol Formel
L-Val	C22H25Br2NO5
L-Val	C22H25Br2NO5
L-Tyr	C26H25Br2NO6
	C23H27Br2NO5



	
	C27H27Br2NO5S
D-Leu	C23H27Br2NO5
D-Tyr	C26H25Br2NO6
D-Trp	C28H26Br2N2O5
L-Arg	C23H28Br2N4O5
L-Abu	C21H23Br2NO5
	C20H21Br2NO5
	C20H21Br2NO5
L-Leu	C23H27Br2NO5
	C25H23Br2NO5
D-Pro	C22H23Br2NO5
L-Ile	C23H27Br2NO5
	C23H25Br2NO5
L-Phe	C26H25Br2NO5
L-Lys	C23H28Br2N2O5
	C23H25Br2NO5
L-Pro	C22H23Br2NO5




20. The compounds as defined in Claim 1 having the structures



or a pharmaceutically acceptable salt or ester(s) thereof.


5

21. The compounds as defined in Claim 1 having the structures



or a pharmaceutically acceptable salt or ester(s) thereof.

22. The compounds as defined in Claim 1 having the structures



wherein R<sub>1</sub> = isopropyl, methyl, ethyl; R<sub>2</sub> and R<sub>3</sub> may be independently selected from Br, Cl and Me; n = 0 or 1; R\* may be hydrogen, alkyl, cycloalkyl, aryl and heteroaryl; \* denotes either D or L stereochemistry when R\* is not hydrogen; R<sub>5</sub> is hydrogen; and R' is selected from hydrogen, lower alkyl, especially ethyl and methyl.

23. A method for preventing, inhibiting or treating a disease associated with metabolism dysfunction, or which is dependent on the expression of a T<sub>3</sub> regulated gene, which comprises administering to a patient in need of treatment a therapeutically effective amount of a compound as defined in Claim 1.

24. The method as defined in Claim 23 wherein the disease associated with metabolism dysfunction or which is dependent on the expression of a T<sub>3</sub> regulated gene is obesity, hypercholesterolemia, atherosclerosis, depression, osteoporosis, hypothyroidism, goiter, thyroid cancer, glaucoma, cardiac arrhythmia, congestive heart failure, or skin disorders.

25. The use of a compound according to Claim 1 in the preparation of a medicament for the treatment of a disease or disorders which is dependent on the expression of a T<sub>3</sub> regulated gene.

26. The use of a compound according to Claim 1 in which the disease or disorder is selected from hypothyroidism, hypercholesterolemia, obesity, skin disorders, glaucoma, cardiovascular disease, congestive heart failure and other endocrine disorders related to thyroid hormone.

27. A pharmaceutical composition comprising an effective amount of a compound according to Claim 1 or a pharmaceutically effective salt thereof, together with a pharmaceutically acceptable carrier.

